Allogene Therapeutics (ALLO) Stock News

Allogene Therapeutics (Nasdaq: ALLO) reported Q3 2025 results and provided program updates on November 6, 2025. Key financials: $277.1M in cash, cash equivalents and investments as of Sept 30, 2025, with cash runway projected into 2H 2027 and an expected 2025 cash decline of ~$150M. Q3 operating metrics: R&D $31.2M, G&A $13.7M, and net loss $41.4M ( $0.19/share). GAAP operating expenses guidance for 2025 is ~$230M including ~$45M stock-based comp.

Clinical milestones: pivotal Phase 2 ALPHA3 futility analysis (MRD conversion) on track for 1H 2026; ALLO-329 RESOLUTION PoC and biomarker update planned for 1H 2026; ALLO-316 showed durable responses in RCC and TRAVERSE completed Phase 1b enrollment.

Allogene (Nasdaq: ALLO) will present a Trial-in-Progress poster on the pivotal Phase 2 ALPHA3 study at the 2025 ASH Annual Meeting in Orlando.

ALPHA3 is a randomized, open-label trial testing cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation for patients with large B-cell lymphoma (LBCL) who remain MRD-positive after 1L chemoimmunotherapy, comparing cema-cel after standard FC lymphodepletion versus observation. A futility analysis on MRD conversion is expected in 1H 2026. Poster: Session 628, Poster II, Publication 3730; presenter John Burke, MD; display on Dec 7, 2025, 6:00–8:00 PM ET at OCCC West Halls B3-B4.

Allogene Therapeutics (Nasdaq: ALLO) will report third quarter 2025 financial results and provide a business update on November 6, 2025 after market close. A live audio webcast and conference call is scheduled for 2:00 p.m. PT / 5:00 p.m. ET.

The listen-only webcast will be available via the company website under Investors > News and Events, and a replay will be posted for approximately 30 days. Investors who wish to ask questions must register for the conference call to receive a personal PIN to access the call.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in Citi's 2025 Biopharma Back to School Summit.

The presentation is scheduled for Wednesday, September 3, at 7:30 AM PT/10:30 AM ET. Investors can access the webcast through Allogene's website, with replays available for approximately 30 days after the event.

Allogene Therapeutics (Nasdaq: ALLO) reported Q2 2025 financial results and provided significant updates across its clinical pipeline. The company announced the advancement of its pivotal Phase 2 ALPHA3 trial for Cema-Cel in LBCL, now proceeding as a two-arm randomized study with over 50 activated sites. Additionally, Allogene initiated the Phase 1 RESOLUTION trial for ALLO-329 in autoimmune diseases and presented updated ALLO-316 results in renal cell carcinoma at ASCO 2025.

Financial highlights include a Q2 2025 net loss of $50.9 million ($0.23 per share) and a strong cash position of $302.6 million, extending runway into 2H 2027. R&D expenses were $40.2 million, while G&A expenses totaled $14.3 million for the quarter.

[ "Strong cash position of $302.6 million with runway extended into 2H 2027", "Successful expansion to over 50 clinical sites across U.S. and Canada for ALPHA3 trial", "FDA alignment achieved on pivotal trial design for ALLO-316 in solid tumors", "Launch of first autoimmune disease trial with ALLO-329" ]

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, will release its Q2 2025 financial results on August 13, 2025 after market close.

The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the webcast through Allogene's website, while those wishing to ask questions during the call must register separately to receive a personal PIN.

Allogene Therapeutics (NASDAQ:ALLO) has announced a significant change in its ALPHA3 trial for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. The company will proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion regimen, discontinuing the FC plus ALLO-647 (FCA) arm following a patient death attributed to ALLO-647.

The decision was made after a Grade 5 adverse event occurred on Day 54 post-infusion, resulting from hepatic failure due to disseminated adenovirus infection. The trial will now continue as a two-arm randomized study comparing cema-cel with standard FC lymphodepletion to observation. The scheduled futility analysis remains planned for 1H 2026.

Allogene is shifting its clinical strategy, removing ALLO-647 from all trials and advancing next-generation AlloCAR T products using their proprietary Dagger® Platform Technology, designed to minimize or eliminate standard lymphodepletion needs.

Allogene Therapeutics (ALLO) presented promising Phase 1 TRAVERSE trial data for ALLO-316 in treating advanced renal cell carcinoma (RCC). The study demonstrated a 31% confirmed response rate in patients with CD70 TPS ≥50%, with four out of five confirmed responders maintaining ongoing responses, including one lasting over 12 months. The trial enrolled 22 heavily pretreated patients, with 20 receiving ALLO-316 treatment. Using the proprietary Dagger technology, patients received standard lymphodepletion followed by a single dose of 80 million AlloCAR T cells. The safety profile was manageable, with main adverse events including cytokine release syndrome (68%, no grade ≥3), neutropenia (68%), and decreased white blood cell count (68%). The treatment showed particular efficacy in patients with high CD70 expression, marking a significant advancement in allogeneic CAR T therapy for solid tumors.

Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its participation in four major investor conferences:

• TD Cowen's 6th Annual Oncology Innovation Summit (May 27, 9:30AM PT)• Jefferies Global Healthcare Conference (June 4, 1:55PM PT)• Goldman Sachs 46th Annual Global Healthcare Conference (June 10, 5:00AM PT)• Oppenheimer Innovators in I&I Summit (June 25, 9:45AM PT)

Webcasts of the presentations will be available on the company's website (www.allogene.com) under the Investors tab, with replays accessible for approximately 30 days after the events.